What We Offer
CORE CLASSES:
- Products liability (“claims made” basis)
- Public / Pollution liability (“occurrence” basis)
- Clinical Trials liability (legal liability or no fault compensation depending on territory)
SUPPLEMENTARY CLASSES (written in conjunction with core classes):
- Medical Malpractice
- Incidental Product Recall
- Incidental Professional Indemnity
- Incidental / UK Employers’ Liability
PROGRAMME STRUCTURE:
- Primary or “excess of loss” layers
- Direct or facultative reinsurance
What We Target
An extensive range of pharmaceutical and biotech companies including:
- Product licence holders
- Manufacturers
- Distributors/Retailers
- Contract manufacturers
- Biotechnology companies
- Research and Development entities
Sub-Sectors targeted include:
- Patented molecules
- Generic (off patent) drugs
- Final formulation medicines
- Over the counter products
- Pharmaceutical intermediates/catalysts
- Fine chemicals
- Nutraceuticals/health supplements
- Blood fractionators/filtration service providers/blood banks
Why We're Different
- Appetite for US exposures including domiciled sales and manufacturing operations
- Ability to consider US parented companies with up to $150M of US turnover
- Led by in-house expertise – our team includes ex-professionals from the pharmaceutical industry combined with exceptional underwriting experience
- Offering the highest quality clinical trials product with the ability to offer coverage in over 100 countries in local languages (where applicable) and market leading policy periods
- Focus on longevity and depth of relationships with clients and brokers with the ability to back up formally through long term agreements (where appropriate)
- Ability to cover drugs (even on a “standalone drug basis”) others may exclude through exclusion of their known issues/side effects
The Team
Daniel Starmer
Director of Life Science Liability
Anthony Wright
Head of Commercial Liability
James Banks
Director of Healthcare
